As of November 10, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of InMed Pharmaceuticals, Inc. The largest reported stake is Vivo Opportunity Fund Holdings, L.P.'s, at 21.7%. 6 filings are on record since January 20, 2026 (Schedule 13D, June 10, 2026).
Sell to companies like InMed Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: ADAR1 Capital Management, LLC · Sole voting: 0 · Shared voting: 943,668 · Sole dispositive: 0 · Shared dispositive: 943,668 · SCHEDULE 13G/A, 2026-10-07
- · Reporting person: Ikarian Capital, LLC · Sole voting: 0 · Shared voting: 137,634 · Sole dispositive: 0 · Shared dispositive: 137,634 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Vivo Opportunity Fund Holdings, L.P. · Sole voting: 718,444 · Shared voting: 0 · Sole dispositive: 718,444 · Shared dispositive: 0 · SCHEDULE 13D, 2026-06-10
- · Holder: ADAR1 Capital Management, LLC · Percent: 24.1% · SCHEDULE 13G
- · Holder: Squadron Master Fund LP · Percent: 9.8% · SCHEDULE 13G
InMed Pharmaceuticals, Inc. has 6 Schedule 13D or 13G filings on record since 2026-01-20. 4 holders' latest filing reports 5% or more of common shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 1 filing or notice, latest 2026-03-06 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 21.7% | 718,444 | SCHEDULE 13D, 2026-06-10 | 2026-05-19 |
| ADAR1 Capital Management, LLC | 17.2% | 943,668 | SCHEDULE 13G/A, 2026-10-07 | 2026-09-30 |
| Sabby Management, LLC | 9.9% | 280,138 | SCHEDULE 13G, 2026-01-20 | 2025-12-31 |
| Squadron Master Fund LP | 9.8% | 325,000 | SCHEDULE 13G, 2026-05-27 | 2026-05-19 |
| Ikarian Capital, LLC | 4.2% | 137,634 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind InMed Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on InMed Pharmaceuticals, Inc. and the records around it.
InMed Pharmaceuticals, Inc. elsewhere on the record
- Layoff notices Mar 2026
- Who owns it
Companies that share a holder
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)
- SABBY MANAGEMENT, LLC also filed stake reports on 15 other companies: Globavend Holdings Ltd (Jan 2026), Jiuzi Holdings, Inc. (Jan 2026), Tempest Therapeutics, Inc. (Jan 2026)
- Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Compass Therapeutics, Inc. (Aug 2026)
Watch InMed Pharmaceuticals, Inc.
Get an email when InMed Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on InMed Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on InMed Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on InMed Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 718,444 | 0 | 718,444 | 0 | SCHEDULE 13D, 2026-06-10 |
| Vivo Opportunity, LLC | 718,444 | 0 | 718,444 | 0 | SCHEDULE 13D, 2026-06-10 |
| Vivo Opportunity Cayman Fund, L.P. | 72,535 | 0 | 72,535 | 0 | SCHEDULE 13D, 2026-06-10 |
| Vivo Opportunity Cayman, LLC | 72,535 | 0 | 72,535 | 0 | SCHEDULE 13D, 2026-06-10 |
| ADAR1 Capital Management, LLC | 0 | 943,668 | 0 | 943,668 | SCHEDULE 13G/A, 2026-10-07 |
| Daniel Schneeberger | 0 | 943,668 | 0 | 943,668 | SCHEDULE 13G/A, 2026-10-07 |
| Ikarian Capital, LLC | 0 | 137,634 | 0 | 137,634 | SCHEDULE 13G, 2026-08-14 |
| Neil Shahrestani | 0 | 137,634 | 0 | 137,634 | SCHEDULE 13G, 2026-08-14 |
The latest filing identifies InMed Pharmaceuticals, Inc. by CUSIP 457637700 and gives its principal executive office as Suite 1800 - 500 West Georgia St., Vancouver (SCHEDULE 13G/A, 2026-10-07).
Source of funds (Item 3)
The funds used to purchase the securities reported herein came from the working capital of Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P.Vivo Opportunity Fund Holdings, L.P., SCHEDULE 13D, 2026-06-10
Purpose of Transaction (Item 4)
Vivo Opportunity Fund Holdings, L.P.
On May 19, 2026, the Issuer, Indigo Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of the Issuer (the "First Merger Sub"), Indigo Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Issuer (the "Second Merger Sub" and, together with First Merger Sub, the "Merger Subs"), and Mentari Therapeutics, Inc., a Delaware corporation ("Mentari"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), pursuant to which, among other matters and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, (i) the First Merger Sub will merge with and into Mentari, with Mentari surviving the merger as a wholly owned subsidiary of the Company (the "First Merger"), and (ii) immediately following the First Merger and as part of the same overall transaction as the First Merger, Mentari will merge with and into the Second Merger Sub, with the Second Merger Sub surviving such merger (the "Second Merger" and, together with the First Merger, the "Merger"). Subject to the terms and conditions of the Merger Agreement, at the effective time of the First Merger (the "First Effective Time"), each share of Mentari capital stock outstanding immediately prior to the First Effective Time will be converted into the right to receive a number of the Issuer's common shares (the "Common Shares") equal to the exchange ratio determined under the Merger Agreement (the "Exchange …The first part of Item 4 of the SCHEDULE 13D filed 2026-06-10; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-01-20 | Sabby Management, LLC | 9.9% | SCHEDULE 13G |
| 2026-05-27 | Squadron Master Fund LP | 9.8% | SCHEDULE 13G |
| 2026-06-05 | ADAR1 Capital Management, LLC | 24.1% | SCHEDULE 13G |
| 2026-06-10 | Vivo Opportunity Fund Holdings, L.P. | 21.7% | SCHEDULE 13D |
| 2026-08-14 | Ikarian Capital, LLC | 4.2% | SCHEDULE 13G |
| 2026-10-07 | ADAR1 Capital Management, LLC | 17.2% | SCHEDULE 13G/A |
Questions about who owns InMed Pharmaceuticals, Inc.
Who owns InMed Pharmaceuticals, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of InMed Pharmaceuticals, Inc.: Vivo Opportunity Fund Holdings, L.P. (21.7%, Schedule 13D, filed 2026-06-10), ADAR1 Capital Management, LLC (17.2%, Schedule 13G/A, filed 2026-10-07), Sabby Management, LLC (9.9%, Schedule 13G, filed 2026-01-20) and Squadron Master Fund LP (9.8%, Schedule 13G, filed 2026-05-27).
Who are the largest shareholders of InMed Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of InMed Pharmaceuticals, Inc. on this page are Vivo Opportunity Fund Holdings, L.P. (21.7%), ADAR1 Capital Management, LLC (17.2%) and Sabby Management, LLC (9.9%).
When did Vivo Opportunity Fund Holdings, L.P. buy into InMed Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Vivo Opportunity Fund Holdings, L.P. on this page is the Schedule 13D, filed 2026-06-10, reporting 21.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for InMed Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.